Coloplast (CPSE:COLO B) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

COLO B Panoramica delle azioni

Coloplast A/S si occupa dello sviluppo e della vendita di prodotti e servizi per l'igiene intima in Danimarca, Stati Uniti, Regno Unito, Francia e a livello internazionale.

Informazioni sull'azienda

COLO B analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	2/6
Prestazioni passate	2/6
Salute finanziaria	1/6
Dividendi	3/6

Premi

Negoziato a 11.3% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 12.63% all'anno

Gli utili sono cresciuti del 4.9% all'anno negli ultimi 5 anni

Analisi del rischio

Il debito non è ben coperto dal flusso di cassa operativo

Il dividendo di 2.25% non è ben coperto dagli utili o dai flussi di cassa liberi

Gli azionisti sono stati diluiti nell'ultimo anno

Coloplast A/S Concorrenti

Demant

CPSE:DEMANT

DKK 58.8b

Ambu

CPSE:AMBU B

DKK 40.7b

HOYA

TSE:7741

JP¥6.9t

Embla Medical hf

CPSE:EMBLA

DKK 13.2b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Coloplast
Prezzi storici delle azioni
Prezzo attuale dell'azione	DKK 900.80
Massimo di 52 settimane	DKK 977.60
Minimo di 52 settimane	DKK 689.20
Beta	0.32
1Variazione di 1 mese	2.55%
Variazione a 3 mesi	4.82%
Variazione di 1 anno	12.94%
3Variazione a 3 anni	-17.92%
Variazione a 5 anni	11.79%
Variazione dall'IPO	6,949.74%

Notizie e aggiornamenti recenti

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10

Recent updates

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

May 09

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 04

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Nov 16

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Sep 30

Is Coloplast (CPH:COLO B) A Risky Investment?

Jun 28

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Jun 10

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Mar 22

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 01

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 14

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 26

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 11

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Oct 25

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Aug 26

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jul 27

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Jul 12

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

May 23

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

May 08

Coloplast (CPH:COLO B) Seems To Use Debt Rather Sparingly

Apr 13

Here's Why I Think Coloplast (CPH:COLO B) Is An Interesting Stock

Mar 29

Coloplast A/S (CPH:COLO B) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 12

Coloplast (CPH:COLO B) Could Easily Take On More Debt

Jan 12

Is Now The Time To Put Coloplast (CPH:COLO B) On Your Watchlist?

Dec 28

Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Is Not Excessive At All

Nov 25

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

Oct 31

Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly

Oct 02

Do Coloplast's (CPH:COLO B) Earnings Warrant Your Attention?

Sep 16

Does This Valuation Of Coloplast A/S (CPH:COLO B) Imply Investors Are Overpaying?

Aug 02

Rendimenti per gli azionisti

	COLO B	DK Medical Equipment	DK Mercato
7D	-2.1%	0.7%	-0.3%
1Y	12.9%	11.3%	25.4%

Ritorno vs Industria: COLO B ha superato il Danish Medical Equipment che ha restituito 11.3 % nell'ultimo anno.

Rendimento vs Mercato: COLO B ha avuto una performance inferiore al mercato Danish che ha registrato un rendimento 27.3 % nell'ultimo anno.

Volatilità dei prezzi

Is COLO B's price volatile compared to industry and market?
COLO B volatility
COLO B Average Weekly Movement	3.1%
Medical Equipment Industry Average Movement	5.7%
Market Average Movement	4.3%
10% most volatile stocks in DK Market	9.1%
10% least volatile stocks in DK Market	2.8%

Prezzo delle azioni stabile: COLO B non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 3% ) di COLO B è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1954	16,019	Kristian Villumsen	www.coloplast.com

Coloplast A/S si occupa dello sviluppo e della vendita di prodotti e servizi per l'igiene intima in Danimarca, Stati Uniti, Regno Unito, Francia e a livello internazionale. L'azienda opera attraverso i segmenti Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology e Advanced Wound Care. L'azienda fornisce prodotti per la cura delle stomie, tra cui SenSura Mio, che permette di adattarsi alle forme del corpo e di avere una discrezione ottimale per vari tipi di stomie, e soluzioni per la cura delle stomie SenSura, oltre ad accessori per stomie con il marchio Brava.

Coloplast A/S Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Coloplast con la sua capitalizzazione di mercato?
COLO B statistiche fondamentali
Capitalizzazione di mercato	DKK 199.61b
Guadagni(TTM)	DKK 4.97b
Ricavi(TTM)	DKK 26.30b

40.8x

Rapporto P/E

7.7x

Rapporto P/S

COLO B è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
COLO B Conto economico (TTM)
Ricavi	DKK 26.30b
Costo del fatturato	DKK 8.54b
Profitto lordo	DKK 17.76b
Altre spese	DKK 12.79b
Guadagni	DKK 4.97b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Nov 05, 2024

Utile per azione (EPS)	22.09
Margine lordo	67.52%
Margine di profitto netto	18.88%
Rapporto debito/patrimonio netto	142.3%

Come si è comportato COLO B nel lungo periodo?

Vedi performance storica e confronto

Dividendi

2.3%

Rendimento attuale del dividendo

95%

Rapporto di remunerazione

COLO B Panoramica delle azioni

Premi

Analisi del rischio

Coloplast A/S Concorrenti

CPSE:DEMANT

DKK 58.8b

CPSE:AMBU B

DKK 40.7b

TSE:7741

JP¥6.9t

CPSE:EMBLA

DKK 13.2b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

Recent updates

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

First half dividend of kr.5.00 announced

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings: EPS misses analyst expectations

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Coloplast A/S Approves the Distribution of Year-End Dividend

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Is Coloplast (CPH:COLO B) A Risky Investment?

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

First quarter 2023 earnings: EPS misses analyst expectations

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of kr.15.00 per share

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Third quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?